The Most Common Barriers to Glaucoma Medication Adherence

Newman-Casey, Paula Anne; Robin, Alan L.; Blachley, Taylor; Farris, Karen B.; Heisler, Michele; Resnicow, Ken; Lee, Paul P.

doi:10.1016/j.ophtha.2015.03.026

Cited by 355 publications

(343 citation statements)

References 53 publications

Supporting

Mentioning

288

Contrasting

Unclassified

Order By: Relevance

“…3 This was accomplished in a predetermined time of 10 minutes, and was followed by a member of the research, trained to answer the patients' questions.…”

Section: (A) I Believe That the Glaucoma Does Not Cause Vision Loss mentioning

confidence: 99%

“…Because glaucoma is an initially asymptomatic disease 2 , low adhesion to antiglaucomatous eyedrops ranges from 30 to 80% in the literature 3 . It is known that inappropriate use of eyedrops is related to the bad control of intraocular pressure and thus to optic neuropathy leading to vision loss.…”

mentioning

confidence: 99%

“…There are several reasons in the literature which lead to non-adhesion of patients with glaucoma to eyedrops that can be cited as a cause leading the patient to not use their eye drops properly, such as the lack of knowledge about the disease, forgetfulness, lack of confidence in the doctor, the side effects of eyedrops, and even the fact that the patient does not understand well the disease nor believes that it causes blindness 3 .…”

mentioning

confidence: 99%

“…The Morisky Accession scale is one of the most validated questionnaires used to assess the adhesion to medication that has been used not only in ophthalmology, but mainly in glaucoma, 3,[7][8][9][10][11][12] as well as other chronic diseases such as diabetes, osteoporosis, hypertension, epilepsy, transplants in use of immunosuppressants, among other chronic diseases. [13][14][15][16][17][18] This scale of 8 items (Morisky Medication Adhesion Score-MMAS-8) has already been validated in Portuguese for HAS 19 .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky Score: a cross sectional study

Ribeiro¹,

Ribeiro²,

Ribeiro³

et al. 2016

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

Objetivo: Determinar a adesão aos colírios antiglaucomatosos em pacientes do Projeto Glaucoma (Ministério da Saúde) por meio da escala de Morisky de 8 itens. Métodos: Foi realizado um estudo transversal por meio de questionário aplicado a 237 pacientes diagnosticados com glaucoma inscritos regularmente no Projeto Glaucoma do Instituto de Olhos de Maceió, adaptando a escala de Morisky já validada em português para colírios. As variáveis foram a adesão aos colírios antiglaucomatosos, idade, sexo, raça, tempo de diagnóstico do glaucoma, número de colírios utilizados, doenças sistêmicas, escolaridade, perfil de visão (ruim, razoável ou boa) e os fatores correlacionados com a adesão. A análise estatística entre as variáveis foi realizada com os testes estatísticos do Quiquadrado para as variáveis categóricas e Teste U de Mann-Whitney para as contínuas, considerando um nível de significância de 5%. Resultados: A adesão aos colírios foi de 54%. A idade e o número de colírios (p=0,02 e 0,03 respectivamente) foram estatisticamente relevantes, assim como a qualidade de visão também foi (p<0,001) para o não uso adequado do tratamento. O motivo mais comum tanto no grupo de aderentes como no de não aderentes foi o esquecimento (23% e 76,15% respectivamente). Conclusão: Utilizando a escala de Morisky adaptada para colírios antiglaucomatosos a adesão aos colírios foi de 54% .Descritores: Adesão ao tratamento/estatística & dados numéricos; Cooperação do paciente; Recusa do paciente ao tratamento; Soluções oftálmicas/uso terapêutico; Glaucoma/quimioterapia ABSTRACT Objective: To determine adherence to glaucoma eye drops in patients from Glaucoma Project (Ministry of Health) by Morisky scale of 8 items. Methods: We conducted a cross-sectional study through a questionnaire applied to 237 patients diagnosed with glaucoma regularly enrolled in the Glaucoma

show abstract

“…3 This was accomplished in a predetermined time of 10 minutes, and was followed by a member of the research, trained to answer the patients' questions.…”

Section: (A) I Believe That the Glaucoma Does Not Cause Vision Loss mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky Score: a cross sectional study

Ribeiro¹,

Ribeiro²,

Ribeiro³

et al. 2016

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…Common barriers to instilling eyedrops include low self‐efficacy, forgetfulness and difficulty with drop administration and medication schedules (Kashiwagi & Furuya 2014; Newman‐Casey et al. 2015). In addition, multidrug therapies may induce chronic ocular surface disease (Baudouin et al.…”

Section: Introductionmentioning

confidence: 99%

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients

Aihara

Adachi

Matsuo

et al. 2017

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo compare the additive effects and safety of 1% brinzolamide/0.5% timolol fixed combination (BTFC) versus the low‐dose regimen of 1% dorzolamide/0.5% timolol fixed combination (DTFC) in patients with open‐angle glaucoma and ocular hypertension (OAG/OH) following treatment with prostaglandin analogues (PGAs).MethodsA prospective, randomized, double‐masked, multicentre, parallel‐group and active‐controlled study included 201 Japanese OAG/OH patients who had been treated with PGA. Efficacy was assessed as the change in intra‐ocular pressure (IOP) from baseline after weeks 4 and 8. Safety was assessed with adverse event rates, ocular discomfort score, blur scale, blood pressure and heart rates, best‐corrected visual acuity (BCVA) and slit lamp examinations.ResultsIntra‐ocular pressure (IOP) change from baseline at 9 AM/11 AM pooled over the 8 weeks was −3.3/−3.3 mmHg in the BTFC group and −2.9/−3.4 mmHg in the DTFC group, demonstrating non‐inferiority of BTFC to DTFC. Ocular irritation was frequently seen in DTFC group. Although blurred vision was frequently seen in BTFC group, it was transient and blurring became the equivalent 3 min after instillation between two groups. No noteworthy issue was observed in other safety outcome.ConclusionNon‐inferiority of BTFC to DTFC in IOP reduction was demonstrated after adding onto PGA therapy in Japanese OAG/OH patients. Although the score of blurred vision was transiently higher in BTFC than DTFC, treatment difference decreased and disappeared with time. Thus, BTFC can be considered as a safe and effective agent for glaucoma treatment.

show abstract

A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery

Zhao

Rahmathullah²,

Almobarak

et al. 2018

JAMA Ophthalmol

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Medical and surgical interventions for glaucoma are effective only if they are affordable to patients. Little is known about how affordable glaucoma interventions are in developing and developed countries.OBJECTIVE To compare the prices of topical glaucoma medications, laser trabeculoplasty, and trabeculectomy relative with median annual household income (MA-HHI) for countries worldwide.DESIGN, SETTING AND PARTICIPANTS Cross-sectional observational study. For each country, we obtained prices for glaucoma medications, laser trabeculoplasty, and trabeculectomy using government pricing data, drug databases, physician fee schedules, academic publications, and communications with local ophthalmologists. Prices were adjusted for purchasing power parity and inflation to 2016 US dollars, and annual therapy prices were examined relative to the MA-HHI. Interventions costing less than 2.5% of the MA-HHI were considered affordable. MAIN OUTCOMES AND MEASURESDaily cost for topical glaucoma medications, cost of annual therapy with glaucoma medications, laser trabeculoplasty, and trabeculectomy relative to MA-HHI in each country.RESULTS Data were obtained from 38 countries, including 17 developed countries and 21 developing countries, as classified by the World Economic Outlook. We observed considerable variability in intervention prices compared with MA-HHI across the countries and across interventions, ranging from 0.1% to 5% of MA-HHI for timolol, 0.1% to 27% for latanoprost, 0.2% to 17% for laser trabeculoplasty, and 0.3% to 42% for trabeculectomy. Timolol was the most affordable medication in all countries studied and was 2.5% or more of MA-HHI in only 2 countries (5%). The annual cost of latanoprost was 2.5% or more of MA-HHI in 15 countries (41%) (15 developing countries [75%] and no developed countries). The cost of laser trabeculoplasty was 2.5% or more of the MA-HHI in 15 countries (44%) (11 developing countries [65%] and 4 developed countries [24%]). The cost of trabeculectomy was 2.5% or more of the MA-HHI in 28 countries (78%) (18 developing countries [95%] and 10 developed countries [59%]). In 18 countries (53%), laser trabeculoplasty cost less than a 3-year latanoprost supply.CONCLUSIONS AND RELEVANCE For many patients worldwide, the costs of medical, laser, and incisional surgical interventions were 2.5% or more of the MA-HHI. Successfully reducing global blindness from glaucoma requires addressing multiple contributing factors, including making glaucoma interventions more affordable.

show abstract

The Most Common Barriers to Glaucoma Medication Adherence

Cited by 355 publications

References 53 publications

Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky Score: a cross sectional study

Adherence assessment of eye drops in patients with glaucoma using 8 item Morisky Score: a cross sectional study

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients

A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery

Contact Info

Product

Resources

About